|
|
|
| Effect of Additional Use of Pidotimod Therapy on Levels of Serum Inflammatory Factors and Immune Function in Children with Tonsillitis |
| WU Yunfei |
| Huai'an Maternal and Child Health Care Center, Jiangsu Huaian 223002, China |
|
|
|
|
Abstract Objective: To investigate the effect of additional use of pidotimod therapy on levels of serum inflammatory factors and immune function in children with tonsillitis. Methods: 240 cases of children with tonsillitis admitted in our hospital from January 2015 to August 2016 were enrolled in the study, and they were divided into control group (treated with routine drugs, n=140) and observation group (additionally treated with pidotimod therapy, n=100) by the random number table method. The serum inflammatory factors [interleukin -4 (IL-4), interleukin -6 (IL-6), interferon γ (IFN- γ)], the immune function [T cell subsets (CD3+, CD4+, CD8+)], the relief of clinical symptoms (duration of fever, duration of cough, duration of tonsil inflammation), recurrent frequency after 1 year of treatment and readmission rates in the two groups were observed before and after treatment. Results: There were no significant differences in IL-4, IL-6, IFN-γ, CD3+, CD4+ and CD8+, duration of fever, duration of cough and duration of tonsil inflammation between the two groups before treatment (P > 0.05). After treatment, IL-4, IL-6 and CD8+ in the two groups were significantly decreased, IFN-γ, CD3+ and CD4+ were significantly increased, the duration of fever, duration of cough and duration of tonsil inflammation were significantly shortened, and the changes of the above indexes (except CD4+) were more obvious in the observation group than the control group (P < 0.05). After 1 year of treatment, the recurrent frequency and readmission rate of the observation group were significantly less or lower than those of the control group (P < 0.05). Conclusion: The additional use of pidotimod therapy is effective in the treatment of children with tonsillitis. It can relieve the clinical symptoms and improve the prognosis of children through effective regulation of serum inflammatory factors and immune function.
|
|
|
|
|
|
[1] 吴雄辉,赵斯君,李赟.碘伏联合康复新液辅助治疗儿童急性化脓性扁桃体炎的疗效观察[J].医学临床研究,2015,24(3):436~438.
[2] 刘沁,张兵,谢志萍,等.长沙地区急性下呼吸道感染住院儿童的病毒病原学分析[J].湖南师范大学学报(医学版),2015,35(1):26~31.
[3] 姚榕威,欧阳绍基,谢凤梅,等.慢性扁桃体炎患者手术治疗前后细胞免疫功能的变化[J].海南医学,2016,27(15):2533~2534.
[4] 赵敏.探讨小儿反复呼吸道感染的病因及临床治疗对策分析[J].世界最新医学信息文摘:连续型电子期刊,2015,39(80):58~59.
[5] 丁冬胜,邹敏书,聂国明.小儿化毒散治疗小儿急性化脓性扁桃体炎临床疗效观察[J].华南国防医学杂志,2015,29(1):66~67.
[6] 琚瑞瑞,郭彦荣,赵坤.赵坤教授治疗反复化脓性扁桃体炎经验探析[J].时珍国医国药,2015,36(4):991~992.
[7] 余霞辉,舒红文,罗健,等.金双歧辅助治疗小儿扁桃体炎的临床研究[J].中国微生态学杂志,2016,27(2):169~173.
[8] 张园,许霞青,刘胜洪,等.CCL2、CCL21在慢性扁桃体炎患者扁桃体中的表达和意义[J].华中科技大学学报(医学版),2016,45(5):479~483.
[9] Calderon C,Rivera L,Hutchinson P,et al.T-cell cytokine profiles are altered in childhood asthma exacerbation[J].Respirology,2009,14(2):264~269.
[10] 龙敏,张静,柏凌云.匹多莫德治疗儿童急性化脓性扁桃体炎的疗效观察[J].中国药房,2011,39(18):1701~1703.
[11] 程锦梅,张玲.匹多莫德对哮喘患儿血浆SP、CGRP及免疫水平的影响[J]中南药学,2015,13(3):310~312.
[12] 王冠,李开为.匹多莫德对支原体肺炎患儿免疫及炎性因子的影响[J].临床肺科杂志,2014,19(5):823~825.
[13] 李婕.玉屏风颗粒联合匹多莫德对儿童反复呼吸道感染的疗效及对免疫功能和炎性细胞因子水平的影响[J].中药材,2014,37(3):534~537.
[14] Carta S,Silvestri M,Rossi GA.Modulation of airway epithelial cell functions by Pidotimod:NF-kB cytoplasmatic expression andits nuclear translocation are associated with an increased TLR-2 expression[J].Ital Pediatr,2013,39(1):29.
[15] 沈学锋.匹多莫德对慢性扁桃体炎患儿血清白细胞介素4和干扰素-γ的影响[J].医药导报,2017,36(1):53~55. |
|
|
|
2018, Vol. 24 
